Mark D Abel

Title: Mark D Abel: Innovator in Cyclosporine Analogue Molecules

Introduction

Mark D Abel is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cyclosporine analogue molecules. With a total of four patents to his name, his work has implications for immunosuppressive therapies.

Latest Patents

Abel's latest patents focus on cyclosporine analogue molecules modified at amino acids 1 and 3. These analogs of cyclosporin-A include modifications of the substituents at these positions, which are designed to enhance affinity for cyclophilin, including cyclophilin-A. Notably, these compounds exhibit reduced immunosuppressivity compared to cyclosporin-A and its analogs modified solely at position 1. This innovation could lead to more effective treatments with fewer side effects.

Career Highlights

Throughout his career, Mark D Abel has worked with prominent companies in the pharmaceutical industry. He has been associated with Isotechnika Inc. and Ciclofilin Pharmaceuticals Corporation, where he has contributed to groundbreaking research and development in drug formulation and delivery.

Collaborations

Abel has collaborated with esteemed colleagues such as Randall W Yatscoff and Robert T Foster. These partnerships have fostered a collaborative environment that has enhanced the innovation process in his field.

Conclusion

Mark D Abel's work in the development of cyclosporine analogue molecules represents a significant advancement in immunosuppressive therapies. His contributions continue to influence the pharmaceutical landscape, paving the way for future innovations.